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Abstract
AIM: To analyze the combined treatment of resection 
and intraoperative radiofrequency ablation (RFA) for 
multifocal hepatocellular carcinoma in terms of progno-
sis and surgical outcomes.
METHODS: This study was a retrospective case com-
parison study using prospectively collected data. The 
study covered the period from April 2001 to Decem-
ber 2006. The data of 200 patients with histologically 
confirmed hepatocellular carcinoma were reviewed. 
Nineteen patients (17 men and 2 women) having re-
ceived resection in combination with RFA were chosen 
as subjects of the study (the combination group). Fifty-
four patients (43 men and 11 women) having received 
resection alone were selected for comparison (the re-
section group). The two groups matched tumor number 
and tumor size, and all the patients in the two groups 
displayed no tumor rupture, major vascular involvement 
and distant metastasis. Their demographics, preopera-
tive assessment, disease recurrence patterns, overall 
survival and disease-free survival were compared.
RESULTS: In the combination group, the median 
age was 65 years (range, 34-77 years), the median 
tumor number was 3 (range, 2-9), and the median 
tumor size was 6 cm (range, 1.2-14 cm). In the resec-
tion group, the median age was 51.5 years (range, 
27-80 years, P  = 0.003), the median tumor number 
was 3 (range, 2-9, P  = 0.574), and the median tu-
mor size was 6 cm (range, 1-14 cm, P  = 0.782). The 
two groups were similar in characteristics of tumors 
and comorbidities, and had comparable results in pre-
operative liver function tests. All patients had Child-
Pugh class A status. Bilobar involvement occurred in 
14 patients (73.6%) in the combination group and 3 
patients (5.5%) in the resection group (P  = 0.04). Six 
patients (32%) in the combination group and 35 pa-
tients (65%) in the resection group underwent major 
hepatectomy. Thirteen patients (68%) in the combi-
nation group and 19 patients (35%) in the resection 
group underwent minor hepatectomy (P  = 0.012). The 
combination group had fewer major resections (32% 
vs  65%, P  = 0.012), less blood loss (400 vs  657 mL, 
P  = 0.007), shorter operation time (270 vs  400 min, 
P  = 0.001), and shorter hospital stay (7 vs  8.5 d, P  = 
0.042). The two groups displayed no major differences 
in surgical complications (15.8% vs  31.5%, P  = 0.24), 
disease recurrence (63.2% vs  50%, P  = 0.673), hospital 
mortality (5.3% vs 5.6%, P = 1), and overall survival (53 
vs  44.5 mo, P  = 0.496).
CONCLUSION: Safe and effective for selected patients 
with multifocal hepatocellular carcinoma, the combina-
tion of resection and intraoperative RFA widens the ap-
plicability of surgical intervention for the disease.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Management of  hepatocellular carcinoma (HCC) in pa-
tients with cirrhosis is always a great challenge for clini-
cians. Prognosis of  most HCC patients is poor due to the 
low rate of  tumor resectability (20%-37%)[1,2]. Although 
resection is regarded as the gold-standard treatment for 
HCC, many patients are not suitable for it because of  un-
favorable anatomical location, major vessel involvement, 
multifocal involvement, distant metastasis, or poor liver 
function[3-7]. In the hope of  improving the survival of  
patients having unresectable HCC, locoregional treatment 
aiming at local tumor control has been developed.
Radiofrequency ablation (RFA) is a locoregional treat-
ment which has gained recognition in the management of  
liver diseases including HCC. During RFA treatment, heat 
energy generated by high-frequency alternating currents 
(460-480 kHz) targeted at the living tissues causes pro-
tein denaturation at a temperature of  60℃ through ionic 
vibration; coagulative necrosis of  the target lesion then 
follows. RFA outperforms other locoregional treatments 
by its effective tumor ablation, minimal liver damage, low 
morbidity, and low mortality[3,8-12].
Lately, there have been detailed studies on RFA treat-
ing small HCC as well as isolated reports on the combined 
employment of  resection and RFA for the treatment of  
liver metastasis of  HCC[13-15]. Curley et al[16] reported a 
series of  RFA treatment on 123 patients bearing unresect-
able primary (n = 48) or metastatic (n = 75) liver tumors. 
A total of  169 tumors were ablated with a clearance rate 
of  100%. There was no operative mortality. However, 
the efficacy of  RFA on large tumors is still questionable. 
Although several reports showed that RFA with multiple 
processes and overlap of  ablation zones was feasible for 
treating large liver tumors, the high recurrence rates did 
not favor it as a primary treatment tool for them[17-22]. 
Resection is still considered the first treatment option for 
large HCC.
Patients with multiple HCCs can opt for multiple 
resections, but multiple resections entail a higher risk 
of  liver failure for patients with cirrhosis. Hence, in the 
management of  multifocal HCC, combined employment 
of  resection (for large tumors) and RFA (for small tu-
mors) sounds like a reasonable measure for the achieve-
ment of  complete tumor clearance.
Both resection and RFA are good treatment options 
for HCC while at the same time they both have their 
own limitations. Resection is limited by the patient’s liver 
function and the location of  tumor, and RFA is limited 
to small tumors only. In general, around one-fourth of  
patients with HCC are amenable to surgical intervention, 
and among them, around one-fourth develop multiple 
tumors on presentation. The combination of  resection 
and RFA can subject more patients to potentially cura-
tive surgical intervention.
This study compared the combined treatment of  
resection and RFA with conventional hepatectomy alone 
in terms of  prognosis and surgical outcomes in treating 
multifocal HCC.
MATERIALS AND METHODS
This study was a retrospective case comparison study us-
ing prospectively collected data. In our hospital, the data 
of  all patients of  liver surgery are input into a detailed 
computerized database by the surgeon-in-charge after 
patient discharge. Data collected include demographics, 
preoperative investigation results, operative details, and 
postoperative investigation results. This study covered 
the period from April 2001 to December 2006. The data 
of  200 patients with histologically confirmed HCC were 
reviewed. Nineteen patients having received resection 
in combination with RFA were chosen as subjects of  
the study (the combination group). Fifty-four patients 
having received resection alone were selected for com-
parison (the resection group). The two groups matched 
in terms of  tumor number (range, 2-9) and tumor size 
(within 14 cm), and all patients in the two groups dis-
played no tumor rupture, major vascular involvement 
and distant metastasis. Their demographics, preoperative 
assessment, disease recurrence patterns, overall survival 
and disease-free survival were compared.
All the 73 patients had their medical history reviewed 
and were fully assessed with physical examination. They 
received chest X-ray (CXR) and computed tomography 
(CT) scan of  the abdomen. They also received serum 
laboratory tests which yielded information on complete 
blood count, platelet count, coagulation profile, hepatitis 
B and hepatitis C serology, total serum bilirubin, serum 
albumin, serum alanine aminotransferase, serum aspartate 
aminotransferase, serum gamma-glutamyl transferase, 
serum alkaline phosphatase, serum α-fetoprotein (AFP), 
electrolytes, renal function, and indocyanine green (ICG) 
clearance rate. Resectability of  tumor was confirmed 
upon three criteria: first, there was no distant metastasis 
according to the results of  CXR and CT scan; second, the 
ICG rate was less than 14.4% at 15 min; and third, the 
estimated mass volume of  the residual liver after resection 
was more than 30% of  the original liver.
Surgical approaches
Each patient in the combination group underwent resec-
tion and RFA in one single operation intended to cure. 
The operation was performed with the open approach, 
starting with an initial exploration of  the abdomen and 
pelvis to confirm the absence of  extrahepatic lesion. 
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Intraoperative ultrasound was used to identify tumor 
location and number as well as the relation between 
the tumors and the vasculature of  the liver. Anatomical 
resection was performed for the largest tumors or the 
largest groups of  tumors which were deemed surgically 
resectable with clear margins. The extent of  resection 
was determined by lesion location, the relation between 
the lesion and the surrounding vasculature, and biliary 
involvement. Parenchymal transection was performed 
with a Cavitron ultrasonic surgical aspirator. Segmental 
pedicles and other major vasculatures were divided with 
vascular staplers or ligatures. Pringle’s maneuver was not 
applied.
Lesions not treated with resection were then sub-
jected to RFA with standard treatment algorithm. Intra-
operative ultrasound was used to guide the placement of  
the RFA needle at the target lesion. Single needle or nee-
dle cluster was used according to the size of  the target 
tumor. For tumors larger than 3 cm, cluster probe was 
used. A margin of  1 cm was included in ablation. The 
Cool-tip™ system which consisted of  a generator that 
supplied power up to 200 W was used. The electrode 
was optimally positioned to achieve complete tumor de-
struction and a normal parenchymal ablation zone of  at 
least 1 cm.
All the patients were originally enlisted for resection 
only, but due to various reasons, the operative surgeon 
adopted RFA as an additional treatment modality with cu-
rative intention for complete control of  tumors. The rea-
sons for the adoption of  a combination therapy are listed 
in Table 1.
Postoperative follow-up
Monitoring of  complete blood picture, coagulation 
profile, blood gas, liver function and renal function was 
carried out on day 1 and day 7 as part of  the standard 
protocol. ICG clearance test was done on day 7 if  pos-
sible. CXR, CT scan of  the abdomen and serum AFP in-
vestigation were performed at one month, then quarterly 
in the first two years, and half-yearly afterwards.
Statistical analysis
All clinical data were analyzed with SPSS version 11.5 un-
der the Window 98 operating system. Categorical variables 
were compared by a χ2 test or Fisher’s exact test. Continu-
ous variables were compared by the Mann-Whitney U 
test. Survival rates were calculated by the Kaplan-Meier 
method, and differences in survival were analyzed by 
the log rank test. P value < 0.05 was considered statisti-
cally significant. The primary outcome measurement was 
overall survival and the secondary outcome measurement 
was disease-free survival. Immediate postoperative perfor-
mance was also analyzed.
RESULTS
In the combination group, 17 men and 2 women, the me-
dian age was 65 years (range, 34-77 years). The median tu-
mor number was 3 (range, 2-9) and the median tumor size 
was 6 cm (range, 1.2-14 cm). In the resection group, 43 
men and 11 women, the median age was 51.5 years (range, 
27-80 years, P = 0.003). The median tumor number was 
3 (range, 2-9, P = 0.574) and the median tumor size was 
6 cm (range, 1-14 cm, P = 0.782). The two groups were 
similar in characteristics of  tumors and comorbidities, and 
had comparable results in preoperative liver function tests 
on serum bilirubin, serum albumin, prothrombin time, 
platelet count and ICG clearance. All patients in the two 
groups had Child-Pugh class A status (Table 2). Bilobar 
involvement occurred in 14 patients (73.6%) in the combi-
nation group and 3 patients (5.5%) in the resection group 
(P = 0.04).
Six patients (32%) in the combination group and 35 
patients (65%) in the resection group received major 
hepatectomy. Thirteen patients (68%) in the combina-
tion group and 19 patients (35%) in the resection group 
received minor hepatectomy (P = 0.012). The types of  
resection performed are listed in Table 3. In the combi-
nation group, 5 patients had small tumor but received a 
large volume of  resection for clearance, and 5 patients 
had tumors located close to major vessel, bile duct, or 
junction of  hepatic veins. A total of  31 tumors were ab-
lated, and the median size of  the tumors was 1 cm (range, 
1-3.8 cm). Ten patients had 1 tumor ablated, 6 patients 
2, and 3 patients 3. Biopsies of  the ablation sites were 
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Table 1  Reasons for adopting combination therapy  n  (%)
Combination group 
(n  = 19)
Bilobar disease              14 (73.6)
Proximity to major vessel or bile duct 5 (26.3)
Dense adhesion 3 (15.8)
Large resection required for small tumors 5 (26.3)
ICG rate at 15 min > 14.4% 5 (26.3)
Low platelet count (< 100 × 109/L) 3 (15.8)
Severe cirrhosis 9 (47.4)
ICG: Indocyanine green.
Table 2  Patient demographics
Combination 
group (n  = 19)
Resection group 
(n  = 54)
P  
value
Age (yr)   65 (34-77)   52 (27-80) 0.003
Gender (M:F) 17:2 43:11 0.492
Comorbidities 10 (53%) 20 (37%) 0.235
Renal impairment 0 (0%)    2 (3.7%) 1.000
Diabetes mellitus      5 (26.3%)    10 (18.5%) 0.469
Chest infection   1 (5.3%)    3 (5.6%) 1.000
Coronary complications      6 (31.6%)    14 (25.9%) 0.635
Hepatitis B infection    16 (84.2%)    42 (77.8%) 0.745
Hepatitis C infection      2 (10.5%)    2 (3.7%) 0.478
Child-Pugh class A 19 54 1.000
Platelet count (× 109/L)    165 (91-64.5)   177 (86-458) 0.396
ICG (% at 15 min) 11.8 (3-25.7)         9 (3.7-18.2) 0.083
AFP level (ng/mL)      248 (6-38 040)       133 (2-530 600) 0.915
Tumor size (cm)      6 (1.2-14)      6 (1-12.5) 0.782
Tumor number 3 (2-9) 3 (2-9) 0.574
AFP: α-fetoprotein.
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taken and all proven to be positive for HCC. The ablated 
sites were monitored with CT scan with contrast at one 
month, and no incomplete ablation was noted.
The combination group demonstrated certain ad-
vantages over the resection group in terms of  surgical 
outcomes: the former had median blood loss of  400 mL 
(range, 20-1650 mL) whereas the latter had 657 mL (range, 
50-3750 mL) (P = 0.007), the former had median opera-
tion time of  270 min (range, 150-465 min) whereas the 
latter had 400 min (range, 165-773 min) (P = 0.001), and 
the former had median hospital stay of  7 d (range, 1-20 d) 
and the latter had 8.5 d (range, 4-69 d) (P = 0.042). There 
was no difference in overall complications (15.8% vs 
31.5%, P = 0.241) and hospital mortality (5.3% vs 5.6%, 
P = 1) between the two groups. Only one patient from 
the resection group needed blood transfusion. The me-
dian serum bilirubin level at day 1 was 21 µmol/L (range, 
10-37 µmol/L) in the combination group and 25 µmol/L 
(range, 9-110 µmol/L) in the resection group (P = 0.012). 
The median serum albumin level at day 1 was 31.5 g/L 
(range, 10-37 g/L) in the combination group and 32 g/L 
(range, 17-39 g/L) in the resection group (P = 0.215). 
The median serum bilirubin level at day 7 was 18 µmol/L 
(range, 11-27 µmol/L) in the combination group and 
21 µmol/L (range, 3-190 µmol/L) in the resection group 
(P = 0.075). The median serum albumin level at day 7 was 
30 g/L (range, 24-39 g/L) in the combination group and 
32 g/L (range, 26-41 g/L) in the resection group (P = 
0.036).
Histopathology
With regard to the pathology of  tumors, the combi-
nation group and the resection group shared similar 
characteristics. Margin involvement happened on none 
of  the patients in the former group while on 4 patients 
(7.4%) in the latter (P = 0.567). Vascular permeation 
happened on 7 patients (36.8%) in the former group and 
31 patients (57.4%) in the latter (P = 0.123). Microsatel-
lite lesions appeared in 3 patients (15.8%) of  the former 
group and 14 patients (25.9%) of  the latter (P = 0.53). 
Poorly differentiated cell types by Edmondson classifica-
tion appeared in 2 patients (10.5%) of  the former group 
and 8 patients (14.8%) of  the latter (P = 0.857). There 
was no statistical difference in histopathology between 
the two groups (Table 4).
Recurrence
Twelve patients (63.2%) in the combination group were 
found developing recurrence at the end of  the study. In-
trahepatic recurrence occurred in 8 patients (42.1%), and 
among them 4 patients (20.5%) had ablation site local 
recurrence, which happened at a median time of  3.6 mo 
(range, 3-24 mo). Extrahepatic recurrence occurred in 
1 patient (5.3%) and intrahepatic and extrahepatic recur-
rence in 3 (15.8%). In the resection group, 27 patients 
(50%) were found developing recurrence. Among them, 
15 patients (27.8%) had intrahepatic recurrence, 4 patients 
(7.4%) extrahepatic recurrence, and 8 patients (14.8%) in-
trahepatic and extrahepatic recurrence (P = 0.673).
Survival
The median follow-up period was 18.4 mo for the entire 
study period, 21 mo (range, 0.03-53 mo) for the combi-
nation group and 15.1 mo (range, 0.37-68.4 mo) for the 
resection group. No patient was lost to follow-up. The 
rates of  overall survival at 1 year and 3 years were 88.8% 
and 62.6%, respectively for the former group (median 
53 mo), and 88.9% and 51.8%, respectively for the latter 
(median 44.5 mo) (P = 0.496) (Figure 1A). The median 
disease-free survival of  the former was 8.8 mo and that 
of  the latter was 9.8 mo (P = 0.64) (Figure 1B). The two 
groups showed no statistically significant differences in 
survival.
DISCUSSION
A variety of  treatment options are available for HCC. 
Liver transplantation offers good hope of  cure to HCC 
patients, even those with poor liver function. However, 
donated livers are scarce, and patients having tumors 
exceeding the size limit for liver transplant or having low 
score in Model for End-stage Liver Disease are not suit-
able for transplantation. So, the first-line option is still, 
if  technically feasible, hepatectomy[1,4,23,24]. Hepatectomy 
with clear margin can provide long postoperative sur-
vival to patients. Unfortunately, poor liver function poses 
extra challenge to hepatectomy because hepatectomy will 
diminish the already limited liver function reserve, thus 
risking liver failure. In Southeast Asia including Hong 
Kong, HCC patients usually have poor liver function be-
cause their HCC often coexists with hepatitis B cirrhosis. 
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Table 3  Types of resection performed according to Brisbane 
terminology (2005) of liver resection  n  (%)
Combination group 
(n  = 19)
Resection group 
(n  = 54)
Right hepatectomy 1 (5.3)         17 (31.5)
Extended right hepatectomy 0 (0) 6 (11.1)
Right trisectionectomy 0 (0) 2 (3.7)
Left hepatectomy 3 (15.8) 3 (5.6)
Extended left hepatectomy 2 (10.5) 4 (7.4)
Left trisectionectomy 0 (0) 3 (5.6)
Left lateral sectionectomy 3 (15.8) 1 (1.9)
Segmentectomy 1 (5.3)         11 (20.4)
Wedge resection of liver 9 (47.4) 7 (13)
Table 4  Histopathological results of tumors  n  (%)
Combination group 
(n  = 19)
Resection group 
(n  = 54)
P  
value
Margin involvement               0 (0) 4 (7.4) 0.567
Vascular permeation    7 (36.8) 31 (57.4) 0.123
Microsatellite lesion    3 (15.8) 14 (25.9) 0.530
Poorly differentiated 
cell type
   2 (10.5)   8 (14.8) 0.857
Complete ablation 19 (100) -
Histological proof of 
HCC at ablation sites
19 (100) -
HCC: Hepatocellular carcinoma.
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Striking a balance between achieving adequate resection 
and preventing liver failure is not easy at all. In patients 
with multifocal HCC, equilibrium between complete tu-
mor clearance and minimal hepatectomy volume is even 
more difficult to grasp. Multiple partial resections, on the 
one hand, can achieve complete tumor clearance but, on 
the other hand, carry a higher risk of  liver failure with 
doubtful long-term oncological outcomes.
RFA is another treatment option for HCC. Several 
clinical trials showed that RFA was as effective as hepa-
tectomy for HCC smaller than 5 cm with a morbid-
ity rate of  less than 15%[22,25,26]. Hence, RFA has been 
gaining recognition in treating liver cancer including 
advanced HCC. Nonetheless, the efficacy of  RFA on 
larger HCC is still questionable. In a study using a por-
cine model, RFA of  30%-35% of  liver and hepatectomy 
of  the same volume were compared, and it was found 
that the former resulted in significantly adverse systemic 
inflammatory response syndrome[27-29]. Hoshida et al[30] 
showed in another study that large parenchymal RFA 
volume was an independent poor prognostic factor for 
HCC patients. With recent advances in the design of  
radiofrequency electrodes and refinements of  ablation 
techniques, favorable outcomes of  RFA treatment on 
large tumors have been reported. However, extra cau-
tion should always be taken in treating large tumors with 
RFA since ablation of  large tumors is associated with a 
high incidence of  local recurrence, and the large amount 
of  necrotic tissue left behind can cause serious problems 
for the patients. To ensure better outcome of  RFA, care-
ful patient selection, meticulous techniques and close 
monitoring of  hepatic and renal functions after the pro-
cedure are essential.
Combined employment of  hepatectomy and RFA for 
metastatic liver cancer has been documented. This com-
bination of  treatments can improve the tumor resectabil-
ity rate for patients having multiple tumors. In this com-
paratively novel treatment, large tumors are resected and 
smaller ones at difficult locations are ablated. Currently, 
data on its performance in the management of  HCC are 
very limited[14-16,22,25,26,31]. In our present study, the surgical 
outcomes of  the combined treatment of  hepatectomy 
and RFA on patients with multifocal HCC were investi-
gated, and it was shown that patients having bilobar HCC 
could be treated safely with it. In the study, considerably 
less major hepatectomies were performed for the com-
bination group, yet complete tumor clearance was still 
achieved. This is of  crucial importance as hepatectomy in 
a lesser extent means better preservation of  liver reserve, 
less liver failure, and quicker recovery[32,33].
For managing multifocal HCC, one may argue that 
multiple anatomical resections can achieve similar results 
as the combination approach. But in our study, we found 
that there are situations in which the combination ap-
proach is easier, if  not better, than resection alone. First 
of  all, if  a tumor is small but requires a large resection 
volume for tumor clearance, RFA comes in as a safer 
option in terms of  liver function preservation. Secondly, 
if  a tumor is close to an important anatomical structure 
such as major vessels or bile ducts, RFA together with 
bile duct cooling can offer complete tumor clearance, 
obviating major hepatectomy. Thirdly, in the case of  
reoperation at a site where there is dense adhesion, RFA 
is a less traumatic treatment option, as mobilization for 
resection may lead to bleeding problem, especially in pa-
tients with thrombocytopenia and coagulopathy.
In this study, the median age of  the combination 
group was 65 years, which was 13 years older than the 
52-year median of  the resection group. Choice of  treat-
ment was up to individual surgeons. It turned out that 
more elderly patients received the combined treatment. 
This was probably because the combined treatment 
would require less operation time and induce seemingly 
less surgical trauma. The resultant shorter operation 
time, less blood loss and shorter hospital stay have vindi-
cated the postulation.
An ablation rate of  100% was achieved as confirmed 
by CT scan of  the abdomen performed one month after 
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Figure 1  Survival curves showing overall survival and disease-free survival of the two groups of patients. A: Overall survival of patients; B: Disease-free 
survival of patients.
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RFA treatment. The two groups displayed similar recur-
rence patterns. A margin of  1 cm was sought in all resec-
tions and ablations since a 1-cm margin is usually effec-
tive in preventing microscopic involvement by the major 
tumor. However, a clear margin alone is not enough for 
preventing tumor recurrence, as apart from margin in-
volvement, there are other factors affecting recurrence 
such as poorly differentiated cell type, lymphovascular 
permeation, and microsatellite lesion, among which the 
latter two are the most significant independent risk fac-
tors. Unfortunately, we cannot alter these factors even by 
providing generous margins[24].
The combination group had more bilobar cases than 
the resection group (73.6% vs 7.4%). Theoretically, pa-
tients with stage Ⅳa HCC would fare worse[34,35]. The 
predominance of  bilobar disease in the combination 
group also explains why the group had more, though 
not significantly, intrahepatic and extrahepatic recur-
rences. A more advanced stage of  HCC probably entails 
a poorer prognosis in general. Sub-group analysis of  
overall survival of  these patients in the two groups was 
performed, and the median survival was 53 mo in the 
combination group and 44.5 mo in the resection group 
(P = 0.496). No significant difference was noted because 
of  the small sample number in the resection group (n = 
3). In our hospital, the median survival of  patients hav-
ing stage Ⅳa HCC is 10 mo if  they undergo no treat-
ment. In the past, bilobar liver disease was considered a 
contraindication to hepatectomy, but with new tools and 
techniques, the whole concept of  resectability is chang-
ing. Liu et al[36] pointed out that resection offered better 
survival outcomes than non-resectional treatments did 
to HCC patients with stage Ⅳa bilobar disease. For this 
category of  patients, resection in combination with RFA 
is an attractive choice of  treatment. As to survival in our 
present study, the combination group and the resection 
group displayed comparable rates of  overall survival and 
disease-free survival.
This study has clearly shown that when complete 
resection by major hepatectomy is dangerous because of  
marginal liver function or difficult tumor location, selec-
tive use of  RFA is helpful. The integration of  RFA into 
resectional surgery contributes to complete removal of  
tumors with adequate margin, diminishes the extent of  
parenchymal resection, and improves the resectability 
rate for patients with stage Ⅳa liver disease. Safe and 
quick, it is especially handy when unexpected tumor is 
discovered during laparotomy, allowing complete tumor 
clearance in an unplanned situation during surgical op-
eration without altering the original plan of  treatment 
procedure too much; this is particularly important to 
patients having marginal hepatic function.
Fresh hope emerges as tumors previously considered 
unresectable due to multifocal involvement or poor liver 
function reserve can now be removed by the combined 
treatment, a new option in treating HCC. At present, a 
randomized controlled trial comparing it with surgical 
resection alone in patients with multifocal HCC is much 
desirable.
COMMENTS
Background
Management of hepatocellular carcinoma (HCC) in patients with cirrhosis is 
always a great challenge for clinicians. Prognosis of these patients is poor 
because many of their tumors are unresectable (with a resectability rate of 
20%-37% only). Although resection is regarded as the gold-standard treatment 
for HCC, it is not applicable to cases with unfavorable anatomical location, 
major vessel involvement, multifocal involvement, distant metastasis, or poor 
liver function. On the other hand, radiofrequency ablation (RFA) is a treatment 
which has been gaining more and more recognition in the management of liver 
diseases including HCC. Both resection and RFA are good treatment options 
for HCC. However, they have their own limitations. Resection is hampered by 
patient’s liver function as well as the location of tumor, whilst RFA is limited 
to smaller tumors only. In reality, only around one-fourth of HCC patients are 
amenable to surgical intervention, and in this sub-group, around one-fourth de-
velop multiple tumors on presentation. There is no doubt that the combination 
of resection and RFA can subject more patients to potentially curative surgical 
intervention. The present study compared the combined treatment of resection 
and RFA with the treatment of sole resection and investigated the surgical out-
comes of the combined treatment in patients with multifocal HCC.
Research frontiers
There is no detailed report on the combined use of resection and RFA in the 
management of HCC. However, this is an important topic as treating HCC with 
RFA is getting popular, and combining RFA with resection can definitely extend 
the operability of surgical intervention to patients with multifocal HCC.
Innovations and breakthroughs
In the management of multifocal HCC, one may argue that multiple resections 
can achieve what the combined treatment achieves, and thus there is no need 
to call in RFA. However, in the present study, it has been found that in some 
situations the combined treatment is easier than resection alone. First of all, 
since RFA is less traumatic and hence better for liver function preservation, it is 
preferable to resection when the tumor is small but still requires a large volume 
of resection for tumor clearance. Secondly, when the tumor is close to an impor-
tant anatomical structure such as major vessel or bile duct, RFA together with 
bile duct cooling can achieve complete tumor clearance with lower risk. Thirdly, 
if dense adhesion is encountered, which is not uncommon in re-operation, RFA 
is safer as mobilization of the liver for resection may lead to bleeding problem 
especially in patients with thrombocytopenia and coagulopathy.
Applications
This study has clearly shown that when complete resection by major hepatec-
tomy is dangerous because of marginal liver function or difficult tumor location, 
selective use of RFA provides the benefit of increased tumor resectability. The 
integration of RFA into resectional surgery contributes to complete removal of 
tumors with adequate margin, diminishes the extent of parenchymal resection, 
and improves the resectability rate for patients with stage Ⅳa liver disease. 
Being safe and quick, it is especially handy when unexpected tumor is encoun-
tered during laparotomy, allowing achievement of complete tumor clearance 
in an unplanned situation during surgical operation without altering the original 
plan of treatment procedure too much; this is particularly important to patients 
with marginal liver function.
Terminology
RFA is a locoregional treatment. RFA treats tumors by inducing coagulative 
necrosis of the target lesion. During RFA, heat energy generated by high-
frequency alternating currents (460-480 kHz) targeted at the lesion through 
ionic vibration causes protein denature at a temperature of 60℃, which causes 
coagulative necrosis of tissues.
Peer review
The Hong Kong group describes their experience with surgical treatment of 
HCC by performing a retrospective analysis of resected-only patients versus 
resected + RFA patients with HCC. This is important data to present and very 
clinically relevant as centers all over the world are taking care of rising numbers 
of patients with HCC. 
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